^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SIR-Spheres (yttrium-90 microspheres)

    i
    Other names: SIR-Spheres Y-90 resin microspheres, selective internal radiation therapy, SIRT, SIR-Spheres microspheres
    Associations

    News

    Trials
    Company:
    SIRTeX Medical
    Drug class:
    Beta radiation emitter
    Related drugs:
    Associations

    News

    Trials
    20d
    SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver (clinicaltrials.gov)
    P2, N=48, Completed, Thomas Jefferson University | Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion • Trial completion date
    |
    SIR-Spheres (yttrium-90 microspheres)
    2ms
    STRATUM: Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients (clinicaltrials.gov)
    P2, N=100, Recruiting, National Cancer Centre, Singapore | N=176 --> 100 | Trial completion date: Oct 2026 --> Jan 2028 | Trial primary completion date: Apr 2025 --> Jul 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • SIR-Spheres (yttrium-90 microspheres)
    3ms
    Yttrium Y-90 Radioembolization in Treating Patients With Metastatic Liver Cancer (clinicaltrials.gov)
    P=N/A, N=12, Active, not recruiting, M.D. Anderson Cancer Center | Phase classification: P1 --> P=N/A
    Phase classification
    |
    SIR-Spheres (yttrium-90 microspheres)
    3ms
    Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer (clinicaltrials.gov)
    P1, N=25, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting | Trial completion date: Aug 2025 --> Feb 2026 | Trial primary completion date: Aug 2025 --> Feb 2026
    Enrollment closed • Trial completion date • Trial primary completion date • Tumor mutational burden
    |
    PD-L1 (Programmed death ligand 1)
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • SIR-Spheres (yttrium-90 microspheres)
    4ms
    Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer (clinicaltrials.gov)
    P2, N=11, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting
    Enrollment open • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Libtayo (cemiplimab-rwlc) • SIR-Spheres (yttrium-90 microspheres)
    7ms
    SIRCCA: SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma (clinicaltrials.gov)
    P2/3, N=89, Terminated, Sirtex Medical | Completed --> Terminated; Slow enrollment
    Trial termination
    |
    cisplatin • gemcitabine • SIR-Spheres (yttrium-90 microspheres)
    9ms
    Yttrium Y-90 Radioembolization in Treating Patients With Metastatic Liver Cancer (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jan 2025 --> Jan 2027 | Trial primary completion date: Jan 2025 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    SIR-Spheres (yttrium-90 microspheres)
    9ms
    Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer (clinicaltrials.gov)
    P2, N=11, Not yet recruiting, City of Hope Medical Center
    New P2 trial
    |
    Libtayo (cemiplimab-rwlc) • SIR-Spheres (yttrium-90 microspheres)
    10ms
    Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer (clinicaltrials.gov)
    P1, N=32, Recruiting, City of Hope Medical Center | Trial completion date: Dec 2024 --> Aug 2025 | Trial primary completion date: Dec 2024 --> Aug 2025
    Trial completion date • Trial primary completion date • Tumor mutational burden • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
    |
    PD-L1 expression
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • SIR-Spheres (yttrium-90 microspheres)
    10ms
    SirTac: Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis (clinicaltrials.gov)
    P2, N=108, Completed, Charite University, Berlin, Germany | Recruiting --> Completed | Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Jul 2022 --> Dec 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    cisplatin • SIR-Spheres (yttrium-90 microspheres)
    1year
    Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China (clinicaltrials.gov)
    P=N/A, N=100, Enrolling by invitation, GrandPharma (China) Co., Ltd.
    New trial
    |
    SIR-Spheres (yttrium-90 microspheres)
    over1year
    DOORwaY90: Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients (clinicaltrials.gov)
    P=N/A, N=100, Active, not recruiting, Sirtex Medical | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    SIR-Spheres (yttrium-90 microspheres)